Last reviewed · How we verify
NCT07197307: CLEAR
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Phase 2 trial testing Loncastuximab Tesirine and Epcoritamab in Aggressive Diffuse Large B-cell Lymphoma in 120 participants. Not yet recruiting.
15 January 2030
Quick facts
| Lead sponsor | Universität Münster |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 120 |
| Start date | 15 October 2025 |
| Primary completion | 15 January 2030 |
| Estimated completion | 15 January 2030 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- Loncastuximab Tesirine and Epcoritamab — full drug profile →
Conditions studied
- Aggressive Diffuse Large B-cell Lymphoma — all drugs for Aggressive Diffuse Large B-cell Lymphoma →
- High-grade B-cell Lymphoma (HGBL) — all drugs for High-grade B-cell Lymphoma (HGBL) →
- Follicular Lymphoma (FL) Grade 3B — all drugs for Follicular Lymphoma (FL) Grade 3B →
Sponsor
Universität Münster — full company profile →
Who can join
18 and older, any sex, with Aggressive Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma (HGBL). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a phase II study designed to evaluate the toxicity and efficacy of the combination of loncastuximab tesirine and epcoritamab in patients with relapsed/refractory aggressive B-cell lymphoma. Chimeric antigen receptor (CAR)-T cell naive patients who have failed first-line therapy and patients who have received CAR-T cells as second-line therapy and experienced CAR-T failure will be eligible for inclusion.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Molecular Mechanisms of Resistance to Bispecific Antibodies in Diffuse Large B-Cell Lymphoma.
Maher N, Al Deeban B, Diop NM, Assaf J, et al · · 2026 · PMID 42121895 · DOI 10.3390/cells15090794
Verify or expand the search:
- PubMed search for NCT07197307
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Universität Münster trials
Trials by the same sponsor.
- NCT06912529 — Axicabtagene Ciloleucel CAR T-cells in Patients With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma · Phase 2 · terminated
- NCT06665724 — Clinical Trial Evaluating Safety of 5-Aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodyna · Phase 1 · completed
- NCT06727851 — ESGE-Quality Improvement in Endoscopy: ERCP · enrolling by invitation
- NCT06021288 — Standard Dose Continuous Renal Replacement Therapy (CRRT) Versus Low-Dose CRRT ( KETZEREI ) · NA · recruiting
- NCT06095713 — German Observational Multicenter Study of Patients With Fabry Disease Under Enzyme Replacement Therapy With Pegunigalsid · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07197307 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Universität Münster
- Last refreshed: 29 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07197307.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing